Endocrine Abstracts

Background: A quarter of UK children now leave primary school obese. Childhood obesity is associated with significant comorbidity including obstructive sleep apnoea, type 2 diabetes, non-alcoholic fatty liver disease, hypertension and depression. We report our experience of using semaglutide, a weekly subcutaneous GLP1 receptor agonist, as a weight-loss adjunct for severely obese children in combination with dietary and lifestyle support from a multidisciplinary team.<p cl...

Introduction: Paediatric obesity is associated with significant long-term complications. This study investigated features of metabolic syndrome, non-alcoholic fatty liver disease (NAFLD) and obstructive sleep apnoea (OSA) aiming to establish their incidence and identify any predictive factors.Methods: A retrospective review of case notes was performed for children aged 2-16 years managed for investigation and management of obesity within a single tertiar...

Introduction: Type 2 diabetes mellitus is a known complication of childhood obesity. It is currently diagnosed by undertaking an oral glucose tolerance test (OGTT). Continuous glucose monitoring (CGM) is used predominantly by patients with type 1 diabetes mellitus to monitor glucose levels.Aim: The aim of the study was to investigate glycaemic variation in children and adolescents with obesity who have had no evidence of pre-diabetes or type 2 diabetes o...

Introduction: Childhood obesity is associated with several complications related to physical and mental health. Determining health-related quality of life (HRQOL) is an important outcome measure to ensure patients receive the appropriate care.Aim: We report the baseline HRQOL in a group of UK children and adolescents with severe obesity who were managed in a Tier 3 weight management service.Methods: Paediatric quality of life (Peds...

Introduction: Childhood obesity continues to prove a major public health concern, with obesity and metabolic syndrome becoming increasingly prevalent in children and young people with type 1 diabetes mellitus (T1DM). Glucagon-like peptide 1 (GLP-1) therapy has shown promising results for weight loss in adults with type 2 diabetes mellitus (T2DM) and has recently been licensed for the treatment of adolescents living with obesity. Liraglutide has been shown to be beneficial in f...